Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DNL422
- Development stage
- Preclinical
- Lead developer
- Denali Therapeutics
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
DNL422 is an investigational therapeutic developed by Denali Therapeutics for the treatment of Parkinson's disease. It utilizes Denali's proprietary Transport Vehicle (TV) technology, specifically an Oligonucleotide Transport Vehicle (OTV), to target and reduce alpha synuclein (SNCA) in the brain. Alpha synuclein is a protein implicated in the pathogenesis of Parkinson’s disease, and reducing its levels is a promising strategy for modifying disease progression. DNL422 aims to deliver therapeutic agents across the blood-brain barrier more effectively, addressing a key challenge in neurodegenerative drug development[1].
- Other names
- OTV:SNCA
02
Targets
SNCA (Alpha-synuclein)
Beyond the preview
Go deeper on DNL422.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DNL422.